Home / Market News / $TWST
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Baird Maintains Buy Rating on Twist Bioscience and Raises Price Target to $135

Nov 13, 2026, 11:03 PM UTC · Primary ticker $TWST

Baird analyst Catherine Ramsey Schulte reaffirmed a Buy rating on Twist Bioscience (TWST) and increased its price target from $115 to $135. This indicates a more optimistic valuation from the firm, which could positively influence investor sentiment and the stock's short-term price action.

Baird analyst Catherine Ramsey Schulte has reaffirmed a 'Buy' rating on Twist Bioscience (TWST) and raised the price target from $115 to $135. This action signals increased confidence from a notable sell-side firm regarding TWST's future performance and valuation. For traders, this could lead to short-term positive momentum as the market reacts to the upgraded price target, potentially attracting new buyers. The long-term implication depends on whether the company's fundamentals align with this more optimistic valuation, but in the short term, it provides a positive sentiment boost. A key opportunity for traders is to capitalize on any immediate upward price movement driven by this analyst upgrade.

$TWST positive Analyst price target increase and reiterated Buy rating
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.